AI Article Synopsis

  • Respiratory syncytial virus (RSV) poses significant health risks to infants in the US, with exposure timing linked to their birth month; some months lead to higher risks of serious lower respiratory tract infections (LRTI).
  • A study analyzed insurance claims from infants born between July 2016 and February 2020, focusing on their first RSV season and the medical attention required for RSV LRTI, revealing varying risks based on birth month.
  • Infants born from May to September faced the highest risks of medically attended RSV LRTI during their first season, while those born from October to December had higher hospitalization rates; findings support the use of nirsevimab to mitigate these risks.

Article Abstract

Background: Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality among US infants. A child's calendar birth month determines their age at first exposure(s) to RSV. We estimated birth month-specific risk of medically attended (MA) RSV lower respiratory tract infection (LRTI) among infants during their first RSV season and first year of life (FYOL).

Methods: We analyzed infants born in the USA between July 2016 and February 2020 using three insurance claims databases (two commercial, one Medicaid). We classified infants' first MA RSV LRTI episode by the highest level of care incurred (outpatient, emergency department, or inpatient), employing specific and sensitive diagnostic coding algorithms to define index RSV diagnoses. In our main analysis, we focused on infants' first RSV season. In our secondary analysis, we compared the risk of MA RSV LRTI during infants' first RSV season to that of their FYOL.

Results: Infants born from May through September generally had the highest risk of first-season MA RSV LRTI-approximately 6-10% under the specific RSV index diagnosis definition and 16-26% under the sensitive. Infants born between October and December had the highest risk of RSV-related hospitalization during their first season. The proportion of MA RSV LRTI events classified as inpatient ranged from 9% to 54% (specific) and 5% to 33% (sensitive) across birth month and comorbidity group. Through the FYOL, the overall risk of MA RSV LRTI is comparable across birth months within each claims database (6-11% under the specific definition, 17-30% under the sensitive), with additional cases progressing to care at outpatient or ED settings.

Conclusions: Our data support recent national recommendations for the use of nirsevimab in the USA. For infants born at the tail end of an RSV season who do not receive nirsevimab, a dose administered prior to the onset of their second RSV season could reduce the incidence of outpatient- and ED-related events.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212365PMC
http://dx.doi.org/10.1093/jpids/piae042DOI Listing

Publication Analysis

Top Keywords

rsv season
20
infants born
16
rsv lrti
16
rsv
15
birth month
12
infants' rsv
12
respiratory syncytial
8
syncytial virus
8
risk rsv
8
highest risk
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!